Fondation Ipsen at the World Orphan Drug Congress 2025

From 27 to 29 October 2025, the Fondation Ipsen participated in the World Orphan Drug Congress in Amsterdam, one of the leading international gatherings dedicated to innovation and collaboration in the rare disease ecosystem.

Our President took part in two high-level panel discussions, sharing the Foundation’s perspective on how to strengthen support for innovation and equity in rare disease research. The first, entitled “Innovative funding mechanisms and business models to de-risk Orphan Drug investment,” brought together experts including Francis Pang (Orchard Therapeutics) and Stefano Benvenuti (Fondazione Telethon) to explore sustainable approaches to financing research and development in rare diseases.

The second panel, “Ask the investors: how to attract interest and investment to your start-up,” featured a dynamic exchange with Thom Frielink (Curie Capital BV), Kevin Hammon (EQT Life Sciences) and Pernille Amalie Storm (Access Elevate). The discussion provided valuable insights into the evolving investment landscape and the opportunities for collaboration between science, philanthropy, and venture capital to accelerate innovation for patients.

Beyond the panels, the Congress offered a unique opportunity to connect with partners and stakeholders from around the world. The Fondation Ipsen team held productive meetings and catch-ups with key actors in the field, including Rare Diseases International and MW Advocacy Solutions, reaffirming our shared commitment to advancing solutions for people living with rare diseases.

We are already looking forward to next year’s edition of the World Orphan Drug Congress,and to further contribute to improving the lives of people living with rare diseases worldwide.